

Taddle Creek

MEDICAL DIRECTIVE

Family Health Team

Title:	Uncomplicated Urinary Tract Infection	Number:	TCFHT-MD07
Activation Date:	18-September-2011	Review Date:	05-October-2020
Next Review Date:	05-October-2021		

Sponsoring/Contact Victoria Charko

Person(s)

790 Bay Street, Suite 522 Toronto, Ontario M5G 1N8

(name, position, contact particulars):

416-591-1222

Dr. Alissia Valentinis 790 Bay Street, Suite 522 Toronto, Ontario M5G 1N8

416-591-1222

Sherry Kennedy, Executive Director - skennedy@tcfht.on.ca

790 Bay Street, Suite 306 Toronto, Ontario M5G 1N8

416-260-1315 x 307

Order and/or Delegated Procedure:	Appendix Attached: X No Yes Title:

Using this directive, the implementer is able to assess, diagnose and treat uncomplicated urinary tract infections (UTIs) during in-person patient encounters.

Recipient Patients:	Appendix Attached: No _X_ Yes	
	Title: Appendix A – Authorizer Approval Form	

Recipients must:

- Be active patients of a TCFHT primary care provider who has approved this directive by signing the Authorizer Approval Form
- Be female and 16 years of age or older
- Meet the conditions identified in this directive

Authorized Implementers:	Appendix Attached: No _X_ Yes	
	Title: Appendix B – Implementer Approval Form	

Implementers must be TCFHT-employed Regulated Health Care Providers or Physician Assistant (under the supervision of a physician).

Implementers must complete the following preparation and sign the Implementer Approval Form:

- Assess own knowledge, skill and judgment to competently assess, diagnose and treat uncomplicated urinary tract infections
- Review "Acute simple cystitis in women" from UpToDate, accessible from https://www.uptodate.com/contents/acute-simple-cystitis-in-women
- Review guidelines for collecting a clean catch (midstream) urine specimen, accessible from https://medlineplus.gov/ency/article/007487.htm
- Obtain most recent edition of "Anti-infective Guidelines for Community-acquired Infections" (Anti-Infective Review Panel, 2019) and review the Acute Urinary Tract Infection – Female: Uncomplicated section. Can be purchased from https://www.mumshealth.com/guidelines-tools/anti-infective.
- Review page 1 of "Antibiotics & Common Infections: Stewardship, Effectiveness, Safety & Clinical Pearls", accessible from https://www.pharmacists.ca/cpha-ca/assets/File/education-practiceresources/WebinarSlideDeck/2017/AntibioticsCommonInfectionsNewsletter2016.pdf
- Review mechanisms of action of recommended antibiotics in pharmacology reference textbook and/or Compendium of Pharmaceuticals and Specialties (CPS)
- An authorizing Primary Care Provider must supervise 3 cases

Indications:	Appendix Attached: X No Yes
	Title:

- Female patients presenting with 1 or more of the following: dysuria, frequency, urgency, suprapubic pain or pressure
- Midstream urine specimen reveals presence of leukocytes (more than trace amount) or presence of nitrites (any positive, including trace amount) on testing with chemical reagent strip
- Temperature < 38.0°C without antipyretics

Contraindications:

- Male, under 16 years of age, pregnant, patients with diabetes and/or severe or complex medical issues
- Temperature > 38.0°C, vomiting or presence of costovertebral angle tenderness
- Patient has a history of urinary calculus
- Patient has a history of frequent UTIs (> 3 in the last year)

For patients presenting with the above contraindications, the implementer obtains history, performs a physical assessment, documents findings and consults with a physician or nurse practitioner in a timely manner for further direction on patient care.

Consent:	Appendix Attached: X No Yes
	Title:

- Patient's consent is implied for implementer to assess and treat uncomplicated UTI, as patient
 has presented seeking treatment and is a Family Health Team patient where interprofessional
 practice is expected
- Patient informed of purpose of testing, as well as when results will be available and that they will be informed of results
- Patient is able to give informed consent and is cooperative
- Patient is informed of the importance of up-to-date contact information in the event of positive results

Guidelines for Implementing the Order/Procedure:

Appendix Attached: ___ No _X Yes

Title: Appendix C – Sample Lab Requisition

Appendix D – Sample Prescription

For assessment and treatment of patients who meet the **Indications** described above:

- Implementer performs assessment including:
 - History (presenting symptoms; urine characteristics; LMP to confirm the patient is not pregnant; past history of UTI and treatment; allergies to antibiotics)
 - Assessment bilaterally for costovertebral angle tenderness to rule out pyelonephritis
 - Temperature
- Implementer obtains a midstream urine sample and applies patient label to specimen bottle. Urine specimen should then be tested with chemical reagent strip using aseptic technique.
- Assess urine characteristics with the sample provided
- If midstream urine specimen reveals presence of leukocytes (more than trace amount) or presence of nitrites (any positive, including trace amount), implementer communicates with patient that she likely has a UTI
- Implementer documents the assessment in the EMR using the TCFHT-MD07 stamp
- Implementer prepares lab requisition for urinalysis and culture & sensitivities using the supervising primary care provider initials in Practice Solutions
- Lab requisition should be signed as below:
 - Signature
 - o Implementer Name/Primary Care Provider Name (Medical Directive TCFHT-MD07)
- Implementer prepares prescription using the supervising primary care provider initials in Practice Solutions
 - Implementer will treat with first line options only, as outlined in the "Acute Urinary Tract Infection – Female: Uncomplicated" section of the most recent edition of Anti-infective Guidelines for Community-acquired Infections
 - If patient has had UTI in past 3 months, consider using a different antibiotic than with which previously treated
 - If patient has had UTI in past 1 month, must repeat urine culture & sensitivities and treat based on results
- Prescription should be signed as below:
 - Signature

- Implementer Name/Primary Care Provider Name (Medical Directive TCFHT-MD07)
- Implementer provides patient with education about common side effects of the antibiotic
 prescribed, when to expect resolution of symptoms, when to seek further medical assistance,
 and prevention of future UTIs (frequent voiding, increasing fluid consumption, perineal hygiene,
 voiding after sexual activity, potential benefits of pure cranberry juice)
- Implementer to follow up with lab results promptly when available and review with the patient's primary care provider

Documentation and Communication:

Appendix Attached: ___ No _X_ Yes
Title: Appendix E – TCFHT-MD07Uncomplicated_Urinary_Tract_Infection Stamp

- Documentation in the patient's EMR needs to include: name and number of the directive and name of the implementer (including credentials) using the following PS Stamp: TCFHT-MD07_Uncomplicated_Urinary_Tract_Infection
- Information regarding implementation of the procedure and the patient's response should be documented in the patient's EMR in accordance with standard documentation practice (College of Nurses, 2008).
- Standard documentation is recommended for prescriptions, requisitions and requests for consultation
- Implementer will send a message in Practice Solutions to patient's primary care provider, notifying him/her that patient was seen and to review note in EMR for details

Review and Quality Monitoring Guidelines:

Appendix Attached:	X	No	Yes	
Title:				

- Routine review will occur annually on the anniversary of the activation date. Review will involve a collaboration between the authorizing primary care providers and the authorized implementers.
- At any such time that issues related to the use of this directive are identified, TCFHT must act
 upon the concerns and immediately undertake a review of the directive by the authorizing
 primary care providers and the authorized implementers.
- This medical directive can be placed on hold if routine review processes are not completed or if
 indicated for an ad hoc review. During the hold, implementers cannot perform the procedures
 under authority of the directive and must obtain direct, patient-specific orders for the procedure
 until it is renewed.
- If new information becomes available between routine reviews, such as the publishing of new "Anti-infective Guidelines for Community-acquired Infections", and particularily if this new information has implications for unexpected outcomes, the directive will be reviewed by the authorizing physician/nurse practitioner and a mimimum of one implementer.

References:

Anti-infective Review Panel. (2019). *Anti-infective guidelines for community-acquired infections.* Toronto: MUMS Health Clearinghouse.

College of Nurses of Ontario. (2008). *Practice Standard: Documentation*. Retrieved from https://www.cno.org/globalassets/docs/prac/41001 documentation.pdf

Hooton, T., & Gupta, K. (2019). *Acute Simple Cystitis in Women*. Retrieved from https://www.uptodate.com/contents/acute-simple-cystitis-in-women

MedLine Plus. (2020). *Clean catch urine sample*. Retrieved from https://medlineplus.gov/ency/article/007487.htm

Rx Files. (2016). *Antibiotics & Common Infections. Stewardship, Effectiveness, Safety & Clinical Pearls*. Retrieved from https://www.pharmacists.ca/cpha-ca/assets/File/education-practiceresources/WebinarSlideDeck/2017/AntibioticsCommonInfectionsNewsletter2016.pdf.

NOTE:

This medical directive is based on TCFHT's previous medical directive RN-1UTI entitled, "Assessment, Diagnosis, and Treatment of Uncomplicated Urinary Tract Infections (UTI)," which required revision in formatting to reflect the growth of the TCFHT organization. The majority of the content of RN-1UTI has remained the same for the revised TCFHT-MD07 version. Therefore, all approved Implementers and Authorizers for medical directive RN-1UTI "Assessment, Diagnosis, and Treatment of Uncomplicated Urinary Tract Infections (UTI)" have grandfathered approval for TCFHT-MD07 "Uncomplicated Urinary Tract Infection."

Appendix A:

Authorizer Approval Form

Name	Signature	Date
	·	
	·	
	·	
		
		
	·	

Appendix B:

Implementer Approval Form

To be signed when the implementer	has completed the required preparation, ar	nd feel they have the
knowledge, skill, and judgement to c	competently carry out the actions outlined in	n this directive.
Name	Signature	Date
		
	-	
	-	
		
	-	
		·
		·
		
	<u> </u>	
		
	-	
	-	· <u></u>

Appendix C:

Sample Lab Requisition

M5G 1N8 (416) 591-1222	
M5G 1N8 (416) 591-1222 Clinician/Practitioner Number CPSO / Registration No. Health Number Version Sex Yyyyy	mm dd Date of Birth mm dd 10 11 contact Number
Cinician/Practitioner Number CPSO / Registration No. Health Number Version Sex Yyyy O18613 ON 1112 223 456 Version Sex OHIP/Insured Third Party / Uninsured WSIB Province Other Provincial Registration Number Patient's Telephone C 416 555-58 Additional Clinical Information (e.g. diagnosis) Patient's Last Name (as per OHIP Card) Duck	Date of Birth mm dd 10 11 1 contact Number
Clinician/Practitioner Number	mm dd 10 11 contact Number
ON 1112 223 456	10 11 contact Number
Additional Clinical Information (e.g. diagnosis) Patient's Last Name (as per OHIP Card) Duck	
Additional Clinical Information (e.g. diagnosis) Patient's Last Name (as per OHIP Card) Duck	555
Duck	,
l	
Patient's First & Middle Names (as per OHIP Card)	
Donald	
Copy to: Clinician/Practitioner Patient's Address (including Postal Code)	
Last Name: First Name	
187 Bay Street Toronto, ON	
Address N4N 5J5	
14410 505	
Note: Separate requisitions are required for cytology, histology / pathology and tests performed by Public Health Laboratory	
x Biochemistry x Hematology x Viral Hepatitis (check	(one only)
Glucose Random Fasting CBC Acute Hepatitis	
HbA1C Prothrombin Time (INR) Chronic Hepatitis	
Creatinine (eGFR) Immunology Immune Status / Previous	s Exposure
Uric Acid Pregnancy Test (Urine) Specify: Hepatitis A	·
Sodium Mononucleosis Screen Hepatitis B	
Potassium Rubella Ulassium Rubella	
Chloride Prenatal: ABO, RhD, Antibody Screen or order individual hepatit "Other Tests" section beld	us tests in the DW
CK (titre and ident. if positive) Prostate Specific Antige Prostate Specific Antige	n (PSA)
	ee PSA
Alk. Phosphatase Microbiology ID & Sensitivities Specify one below:	
Bilirubin (if warranted) ☐ Insured — Meets OHIP eligit	pility criteria
Albumin Cervical Uninsured – Screening: Patier	nt responsible for payment
Lipid Assessment (includes Cholesterol, HDL-C, Triglycerides, Vaginal Vitamin D (25-Hydroxy)	
calculated LDL-C & Chol/HDL-C ratio; individual lipid tests may be ordered in the "Other Tests" section of this form) Vaginal / Rectal – Group B Strep Insured - Meets OHIP eligib	ility criteria:
Albumin / Creatinine Patio, Urine Chlamydia (specific source): osteopenia; osteo	porosis; rickets; labsorption syndromes;
Urinalysis (Chemical) GC (specify source): medications affecti	ing vitamin D metabolism
Neonatal Bilirubin: Sputum ☐ Uninsured - Patient responsit	ole for payment
Child's Age: days hours Throat Other Tests - one test pe	r line
Clinician/Practitioner's tel. no. Wound (specify source):	
Patient's 24 hr telephone no. Urine	
Therapeutic Drug Monitoring: Stool Culture	
Name of Drug #1 Stool Ova & Parasites	
Name of Drug #2 Other Swabs / Pus (specify source):	
Time Collected #1 hr. #2 hr.	
Time of Last Dose #1 hr. #2 hr. Specimen Collection Time Date	
Time of Next Dose #1 hr. #2 hr.	
I hereby certify the tests ordered are not for registered in or Fecal Occult Blood Test (FOBT) (check one)	
out patients of a hospital. FOBT (non CCC)	e ordered on this form
/ Justin M	
Rebekah Barrett, RN	
Medical Directive TCFHT-MD07	
X 09/04/2014 Clinician/Prostitionar Signature	
Clinician/Practitioner Signature Date	

Last Updated 05-10-2020 by Victoria Charko, RN

Apr 9, 2014

Appendix D:

Sample Prescription


Alissia Valentinis M.D., C.C.F.P CPSO #79090 790 Bay Street Suite 522, Box 58/59 Toronto, Ontario M5G 1N8 Tel: 416-591-1222 Fax: 416-591-1227

For:

Donald Duck 187 Bay Street Toronto, ON N4N 5J5

, ON -

DOB: Oct 11, 1930 M 416-555-5555 (H)



Professional ID:

Alissia Valentinis M.D., C.C.F.P.

Appendix E:

TCFHT-MD07_Uncomplicated_Urinary_Tract_Infection Stamp

S:

- Hx of «dysuria,» «urinary frequency,» «urgency,» «suprapubic pain/pressure» X days
- No «fever,» «vomiting,» «back pain»
- «- LMP: •»
- «- No hx of urinary calculus»
- ««- UTIs in the past year«, most recent UTI «weeks» «months» ago»»»
- «Confirmed NKDA» «Allergies to noted»

O:

- T: ●
- «No» «Positive» CVA tenderness
- Urine dip: leuks, nitrites, protein, blood
- Urine characteristics: «clear,» «cloudy,» «hematuria,» «foul smell»

A: «Symptoms consistent with UTI»

P:

- «- Urine sent to lab for C&S and urinalysis»
- «- Rx for given»
- «- Reviewed methods of UTI prevention proper perineal care, good hydration, not holding urine and voiding immediately after sexual activity; discussed benefits of cranberry juice.»
- RTC if symptoms persist or worsen, or if develops fever, vomiting or back pain
- Advised to complete full course of abx, even if symptoms improve/resolve
- Provider to follow up with urine test results

^{*}actions and interventions in accordance with Medical Directive TCFHT-MD07